OVERVIEW
Safety and toxicology is of primary concern to all drug candidates before entering the clinic, and late-stage failures can cost drug developers years of research, not to mention substantial financial losses. Knowledge of the safety of new candidates is as important as their efficacy, and the earlier the characterization of safety risks are made, the greater the ability to curb the occurrence of these late-stage failures is. To this end, we develop a wide variety of cell-based, phenotypic screening assays that can be used to assess broad concerns, such as overall cell death and apoptosis, to specific concerns, such as mitochondrial health or neurite-network disruption. These studies can help risky candidates fail fast, so you can focus on your more-promising treatments.
GENERAL CELL HEALTH OR NEUROTOXICITY
The broadest and quickest assessment of a drug candidate’s overall impact on cell health is to measure its ability to induce cell death or apoptosis. In this assay, a cell type of your choice is treated with your test articles in a dose-response manner, and levels of cell viability and occurrence of apoptosis are measured.

MITOCHONDRIAL HEALTH
Many drugs that have been withdrawn or that have FDA warning labels are traced back to their effects on mitochondrial dysfunction, which can cause failure of various organs. In neurons, mitochondrial-health assessment can be particularly important, as the brain consumes approximately 20% of the body’s energy. Understanding test-article effects on mitochondrial health/function early in drug development is crucial to characterizing drug safety and preventing late-stage or clinical failures.

NEURITE-NETWORK ALTERATIONS
Neurites form the functional network by which neurons connect to enable signal transduction and proper development and differentiation. Neuronal injury or neurotoxicity often feature perturbations in neurite networks, and the assessment of therapeutic candidates’ impacts on neurite-network maintenance is crucial to understanding their safety and toxicity.

CELL PAINTING FOR SAFETY SCREENING
Cell Painting allows for the detection of very subtle changes in phenotypic metrics (e.g., cell shape, texture, organelle structures) in cells that result from exposure to chemicals or drug candidates. By calculating phenotypic fingerprints for each treatment paradigm from a set of over one thousand features, your drug candidates’ effects can be compared to a set of reference compounds to predict the safety/toxicity of your candidates. Cell painting can be especially powerful for detecting early signs of cellular stress/damage before cell death occurs.

RELATED RESOURCES
CONTACT US
Let's discuss how we can help with your next study.
Phenotypic Studies to De-risk Alzheimer's Disease R&D
Overview
Learn more about Alzheimer's disease (AD) and review examples of phenotypic studies designed to measure diverse aspects of AD-relevant biology.
Highlights
- Overview of Alzheimer's disease
- Three example studies characterizing the effect of drug candidates on neurite networks and mitochondrial health, microglia phagocytosis, and AAV gene delivery
- Representative images and data
![]()
